Annette Hay

Dr. Annette Hay is an Associate Professor in the Department of Medicine, Division of Hematology at Queen's University. She holds cross-appointments at the Canadian Cancer Trials Group, Queen's Translational Institute of Medicine (TIME), and Queen's Cancer Research Institute. Her research focuses on clinical trial design, hematological malignancies (lymphoma, leukemia, myeloma), health economics, and data-sharing infrastructure.

Education:

• MB ChB (July 2001) - University of Dundee

Research Interests: Dr. Hay specializes in clinical trials methodology, particularly for underrepresented populations (elderly, adolescents/young adults). She investigates cost-benefit analyses of therapies, efficient trial conduct via data linkage, and patient-centered approaches. Key areas include Hodgkin lymphoma prognostication, regenerative medicine applications, and bioinformatics in oncology.

Article Trends: Her work emphasizes novel combination therapies for lymphoma/leukemia, predictive modeling (e.g., E-HIPI index), and economic evaluations of cancer treatments. Recent studies explore CAR T-cell therapy, frailty indices in trial design, and long-term health outcomes in survivors.

Awards: No awards explicitly listed in provided texts.

Grants/Labs: Leads trials through the Canadian Cancer Trials Group. Collaborates with international groups like the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC). Active in Queen's Translational Institute of Medicine's data integration initiatives.

Labs/Teams: Principal investigator in the Canadian Cancer Trials Group and collaborator in the Myeloma Canada Research Network. Engaged with the Terry Fox Research Institute's precision oncology network.